Influence of achieved LVEF on efficacy of dapagliflozin in patients with heart failure with improved ejection fraction: the DELIVER trial

11 May 2024 (10:00 - 10:45)

Organised by:

Video

Sign in for access options

Abstract

Slides

About the speaker

Doctor Sara Rodrigues De Oliveira Siqueira

Brigham and Women's Hospital, Harvard Medical School, Boston (United States of America)

6 More presentations in this session

Presentation thumbnail

Neutrophil-to-lymphocyte ratio (NLR) and mortality in heart failure: analysis of population-level data

Mr M. Morsy (Glasgow, GB)

Abstract Slides Video

Presentation thumbnail

Pain and anxiety in heart failure - findings from FINEARTS-HF

Doctor M. Yang (Nanjing, CN)

Abstract Slides Video

Presentation thumbnail

Prognostic stratification of acute heart failure patients using the 3C-HF SCORE: short vs long term prediction

Doctor M. Gori (Bergamo, IT)

Abstract Slides Video

Presentation thumbnail

Health-related quality of life in women versus men with heart failure across the spectrum of LVEF

Doctor M. Yang (Nanjing, CN)

Abstract Slides Video

Presentation thumbnail

Machine learning does not improve risk prediction in heart failure in comparison to the PREDICT-HF model: derivation and validation in PARADIGM-HF and ATMOSPHERE

Doctor A. Talebi (Glasgow, GB)

Abstract Slides Video

Access the full session

Session thumbnail

Chronic heart failure - epidemiology, prognosis, outcome 3

The Event

Event poster

Heart Failure 2024

11 May 2024 10:00 CET

You may be interested in

Congress Presentation

Influence of background therapy on efficacy of dapagliflozin in patients with heart failure and improved ejection fraction

Congress Presentation

In-hospital course of patients with heart failure with Improved ejection fraction in the DELIVER Trial

Congress Session

State-of-the art treatment of HFmrEF and HFpEF in 2023